Showing 8461-8470 of 8690 results for "".
- Lambrolizumab Designated as Breakthrough Therapyhttps://practicaldermatology.com/news/20130429-lambrolizumab_designated_as_breakthrough_therapy/2459556/Merck & Co. received breakthrough therapy designation from the US Food and Drug Administration for its lambrolizumab drug as a treatment of patients with advanced melanoma. Lambrolizumab is Merck's investigational antibody therapy targeting Programm
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar
- Web‐Based Supply Chain Management Software Launchedhttps://practicaldermatology.com/news/20130418-webbased_supply_chain_management_software_launched/2459562/Aesyntix Health, Inc. launched the Aesyntix Inventory Management (AIM), a web‐based inventory and automated ordering system to enhance its dermatology supply chain management platform. Specifically for dermatology inventory management, AIM helps
- World's Most Valuable Cosmetics Brands Revealedhttps://practicaldermatology.com/news/20130410-worlds_most_valuable_cosmetics_brands_revealed/2459566/Brand Finance released its annual study of the top 50 most valuable cosmetics brands. Despite a very slight brand value fall, Olay holds its dominant position at the top of the BrandFinance Cosmetics 50 table, with a value of US$11.7 billion. However, Olay's lead at the top has shrunk from US$4 bill
- Dr. Yates Hair Science Group Adopts ARTAS Systemhttps://practicaldermatology.com/news/20130410-dr_yates_hair_science_group_adopts_artas_system/2459568/Restoration Robotics, Inc. installed its revolutionary ARTAS® System at the Dr. Yates Hair Science Group. The ARTAS System is the first and only FDA-cleared, physician-controlled, computer-assisted technology for hair transplantation.
- Houston Surgeon Performs Breakthrough Robotic Hair Restorationhttps://practicaldermatology.com/news/20130402-houston_surgeon_performs_breakthrough_robotic_hair_restoration/2459574/Restoration Robotics, Inc. installed its revolutionary ARTAS System at the Mosaic Clinic in Houston, TX. Dr. Rashid Rashid is one of the few hair physicians in the country to hold both MD and PhD degrees and an enhanced background in r
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al
- Site Aims to Steer Patients to Physicians' Informationhttps://practicaldermatology.com/news/20130401-site_aims_to_steer_patients_to_physicians_information/2459577/Giving patients the proper information has always been important for physicians, and accessible handout literature has been the easiest ways to keep bad information out of their hands. But to keep pace with how quickly patients get their information, Vivacare allows physicians to enroll online free
- Skin Cancer Foundation Inducts Dr. Amy Forman Taub into its Amonette Circlehttps://practicaldermatology.com/news/20130327-skin_cancer_foundation_inducts_amy_forman_taub_md_into_its_amonette_circle/2459579/Amy Forman Taub, MD, was recently inducted into the Skin Cancer Foundation's Amonette Circle at the American Academy of Dermatology Annual Meeting in Miami, FL. Amonette Circle is a lifetime membership comprised of physicians who make an outstanding commitment to The Skin Cancer Foundation's mission
- Valeant Pharmaceuticals to Acquire Obagi Medical Products for Approximately $344 Millionhttps://practicaldermatology.com/news/20130320-valeant_pharmaceuticals_to_acquire_obagi_medical_products_for_approximately_360_million/2459581/Valeant Pharmaceuticals has entered into an agreement to acquire Obagi Medical Products. The transaction values Obagi common stock at approximately $344 million and was unanimously approved by the Obagi Board of Directors. Under terms of the merger agreement, Valeant will commence a tender offer for